Get the Stockscreener App
2.255
12.93%
-0.335
After Hours:
2.28
0.025
+1.11%
Prokidney Corp stock is traded at $2.255, with a volume of 2.90M.
It is down -12.93% in the last 24 hours and down -50.33% over the past month.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
See More
Previous Close:
$2.59
Open:
$2.54
24h Volume:
2.90M
Relative Volume:
0.24
Market Cap:
$384.25M
Revenue:
-
Net Income/Loss:
$-35.47M
P/E Ratio:
-3.9561
EPS:
-0.57
Net Cash Flow:
$-124.27M
1W Performance:
-30.83%
1M Performance:
-50.33%
6M Performance:
+45.48%
1Y Performance:
+3.44%
1-Day Range:
$2.25
$2.60
1-Week Range:
$2.25
$3.33
52-Week Range:
$0.4603
$7.13
Prokidney Corp Stock (PROK) Company Profile
Name
Prokidney Corp
Sector
Industry
Phone
336-999-7028
Address
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
2.255 | 384.25M | 0 | -35.47M | -124.27M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.46 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.94 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.00 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
638.90 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.75 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-30-24 | Initiated | JP Morgan | Neutral |
| Sep-10-24 | Initiated | Guggenheim | Buy |
| Mar-07-24 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-23 | Initiated | BTIG Research | Buy |
| Dec-21-22 | Initiated | Jefferies | Buy |
| Nov-10-22 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-18-22 | Initiated | UBS | Buy |
| Oct-14-22 | Initiated | Citigroup | Buy |
| Sep-23-22 | Initiated | BofA Securities | Buy |
| Sep-02-22 | Initiated | Evercore ISI | Outperform |
View All
Prokidney Corp Stock (PROK) Latest News
ProKidney Shares Double on Strong Phase 2 Data for Kidney Disease Therapy - MSN
ProKidney And 2 Other Penny Stocks To Watch Closely - Yahoo Finance
ProKidney PROK 2025Q2 Earnings Preview Upside Potential on Robust Revenue Growth and Analyst Upgrades - AInvest
What institutional investors are buying ProKidney Corp. stockGet timely alerts on top-performing stocks - Jammu Links News
Meet the Biotech Stock That Rocketed 775% Higher - MSN
What is the dividend policy of ProKidney Corp. stockFree Technical Analysis Support - Jammu Links News
Is ProKidney Corp. stock overvalued or undervaluedInvest confidently with market-leading analysis - Jammu Links News
What catalysts could drive ProKidney Corp. stock higher in 2025Free Stock Market Return Analysis - Jammu Links News
What makes ProKidney Corp. stock price move sharplyGet daily updates on top-performing stocks - Jammu Links News
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study - MSN
What are the technical indicators suggesting about ProKidney Corp.Get exclusive access to premium stock research - Jammu Links News
What analysts say about ProKidney Corp. stockAchieve triple-digit returns with smart investing - Jammu Links News
What are analysts’ price targets for ProKidney Corp. in the next 12 monthsConsistent high-yield stocks - Jammu Links News
Is ProKidney Corp. a growth stock or a value stockHigh-margin investment plays - Jammu Links News
Is it the right time to buy ProKidney Corp. stockAchieve consistent profits with expert strategies - Jammu Links News
How volatile is ProKidney Corp. stock compared to the marketRapid growth opportunities - Jammu Links News
What are ProKidney Corp. company’s key revenue driversCapitalize on emerging market trends - Jammu Links News
When is ProKidney Corp. stock expected to show significant growthDiscover breakthrough trading strategies - Jammu Links News
How does ProKidney Corp. generate profit in a changing economyUnlock rapid growth potential in your portfolio - Jammu Links News
How does ProKidney Corp. compare to its industry peersHigh-octane investment opportunities await - Jammu Links News
ProKidney Shares Surge in Early Trading On FDA Support for Kidney Drug Trial - 富途牛牛
What is ProKidney Corp. company’s growth strategyAdvanced Screener Planner For 2025 - Jammu Links News
Can ProKidney Corp. Regain Lost Ground This QuarterStep-by-Step Stock Investment Guide Gains Popularity - metal.it
How strong is ProKidney Corp. company’s balance sheetAdvanced Screener Planner For 2025 - jammulinksnews.com
How ProKidney Corp. stock performs during market volatilityWeekly Stock Opportunity Radar Scanner Activated - beatles.ru
Published on: 2025-07-30 17:58:00 - beatles.ru
Published on: 2025-07-29 09:29:22 - metal.it
Wyckoff Accumulation Phase Possible in ProKidney Corp.Buy Low Sell High Stock Watch Strategy in Focus - metal.it
Does ProKidney Corp. stock perform well during market downturnsBuild wealth with reliable stock picks - Jammu Links News
Key External Factors That Drive ProKidney Corp. Stock Price MovementsFree Stock Market Group - metal.it
ProKidney Stock Skyrockets But Greensboro Is Still Empty Handed - The Rhino Times of Greensboro -
Is ProKidney Corp. a good long term investmentFree Capital Allocation Plans - PrintWeekIndia
Published on: 2025-07-25 13:32:55 - PrintWeekIndia
ProKidney price target raised to $7 from $6 at Guggenheim - MSN
Prokidney’s REACT Study: A Promising Step for Kidney Disease Treatment - TipRanks
What drives ProKidney Corp. stock priceHigh-octane financial growth - Autocar Professional
BlackRock, Inc. Reduces Stake in ProKidney Corp: A Strategic Por - GuruFocus
ProKidney Corp (PROK) Completes Re-domestication to Delaware amid Kidney Therapy Advancement - MSN
Prokidney Corp Stock (PROK) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
1.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):